Stanley Frankel Buys 2,700 Shares of Precision BioSciences (NASDAQ:DTIL) Stock

Key Points

• Director Stanley Frankel purchased 2,700 shares of Precision BioSciences (NASDAQ:DTIL) stock at an average price of $4.97 per share, increasing his ownership by 19.18%.
• The company reported a disappointing quarterly EPS of ($2.13), significantly missing the consensus estimate of ($0.09), with revenues of only $0.02 million against a forecast of $6.27 million.
• Approximately 37.99% of Precision BioSciences' stock is owned by hedge funds and institutional investors, indicating growing interest in the company.

Precision BioSciences, Inc. (NASDAQ:DTIL - Get Free Report) Director Stanley Frankel purchased 2,700 shares of the firm's stock in a transaction on Friday, September 26th. The stock was acquired at an average price of $4.97 per share, for a total transaction of $13,419.00. Following the completion of the transaction, the director directly owned 16,778 shares of the company's stock, valued at approximately $83,386.66. This trade represents a 19.18% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Precision BioSciences Trading Up 1.4%

Shares of DTIL opened at $5.16 on Tuesday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 5.18 and a current ratio of 5.18. The stock has a market capitalization of $60.84 million, a PE ratio of -0.58 and a beta of 1.61. Precision BioSciences, Inc. has a fifty-two week low of $3.61 and a fifty-two week high of $9.81. The company's fifty day moving average is $4.86 and its 200 day moving average is $4.86.

Precision BioSciences (NASDAQ:DTIL - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($2.13) EPS for the quarter, missing the consensus estimate of ($0.09) by ($2.04). Precision BioSciences had a negative net margin of 6,205.79% and a negative return on equity of 176.47%. The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $6.27 million. Sell-side analysts expect that Precision BioSciences, Inc. will post -1.23 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Precision BioSciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC grew its position in Precision BioSciences by 5.5% in the second quarter. Geode Capital Management LLC now owns 77,712 shares of the company's stock valued at $326,000 after acquiring an additional 4,025 shares in the last quarter. Miller Financial Services LLC acquired a new stake in Precision BioSciences during the first quarter valued at approximately $48,000. Jane Street Group LLC purchased a new stake in Precision BioSciences during the fourth quarter valued at about $146,000. Tejara Capital Ltd lifted its holdings in shares of Precision BioSciences by 185.2% in the first quarter. Tejara Capital Ltd now owns 60,427 shares of the company's stock valued at $288,000 after purchasing an additional 39,242 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new position in shares of Precision BioSciences in the 4th quarter valued at about $179,000. 37.99% of the stock is owned by hedge funds and other institutional investors.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.